Weekly Investment Analysts’ Ratings Updates for Anika Therapeutics (ANIK)

A number of research firms have changed their ratings and price targets for Anika Therapeutics (NASDAQ: ANIK):

  • 7/26/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 7/26/2019 – Anika Therapeutics was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 7/25/2019 – Anika Therapeutics was upgraded by analysts at First Analysis from a “neutral” rating to a “strong-buy” rating. They now have a $54.00 price target on the stock, up previously from $37.00.
  • 7/25/2019 – Anika Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $46.00 price target on the stock. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 7/25/2019 – Anika Therapeutics had its “buy” rating reaffirmed by analysts at Barrington Research. They now have a $49.00 price target on the stock, up previously from $45.00. They wrote, “We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now.””
  • 7/16/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/16/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 7/15/2019 – Anika Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $45.00 price target on the stock. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 7/3/2019 – Anika Therapeutics was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. “
  • 7/3/2019 – Anika Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 6/28/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/22/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/11/2019 – Anika Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Shares of NASDAQ ANIK traded up $0.84 during trading on Tuesday, reaching $55.30. The company had a trading volume of 178,900 shares, compared to its average volume of 182,997. Anika Therapeutics Inc has a 12-month low of $29.01 and a 12-month high of $57.51. The stock has a market cap of $757.78 million, a PE ratio of 30.05, a PEG ratio of 3.14 and a beta of 1.08. The business’s 50-day moving average is $43.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 16.07 and a current ratio of 18.28.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, July 24th. The biotechnology company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.25. Anika Therapeutics had a return on equity of 11.27% and a net margin of 26.87%. The firm had revenue of $30.42 million for the quarter, compared to analysts’ expectations of $27.41 million. During the same period in the prior year, the firm posted $0.68 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. Research analysts forecast that Anika Therapeutics Inc will post 1.75 EPS for the current year.

In other news, Director Raymond J. Land sold 3,000 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $55.44, for a total value of $166,320.00. Following the sale, the director now directly owns 11,992 shares of the company’s stock, valued at $664,836.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.67% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in ANIK. Quantamental Technologies LLC bought a new position in Anika Therapeutics in the first quarter valued at about $69,000. BNP Paribas Arbitrage SA raised its stake in Anika Therapeutics by 356.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,891 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 2,257 shares during the period. Municipal Employees Retirement System of Michigan bought a new stake in Anika Therapeutics during the 4th quarter valued at approximately $140,000. Metropolitan Life Insurance Co. NY raised its stake in Anika Therapeutics by 382.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,141 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 4,075 shares during the period. Finally, SG Americas Securities LLC raised its stake in Anika Therapeutics by 99.8% during the 1st quarter. SG Americas Securities LLC now owns 6,477 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 3,235 shares during the period. 97.41% of the stock is currently owned by institutional investors.

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Read More: What are convertible shares? 

Receive News & Ratings for Anika Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.